Form 4: Aadi Bioscience Director Zhao Baiteng Acquires 1,250,000 Shares of Common Stock

Director Zhao Baiteng reports acquisition of 1,250,000 shares of Aadi Bioscience common stock at $2.4 per share on March 4, 2025.

Summary

• Zhao Baiteng, a director of Aadi Bioscience, Inc., acquired 1,250,000 shares of common stock on March 4, 2025.
• The purchase price was $2.4 per share.
• Following the transaction, Zhao Baiteng beneficially owns 1,250,000 shares indirectly through WZCUBE LLC, where he is the sole manager.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about an insider's activity.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of shares by a director could be viewed positively by shareholders, signaling confidence in the company's future.

Key Dates